Javier Torres-Jiménez

17PUBLICATIONS
63CO-AUTHORS
Early English languagesPredictive and prognostic markersMajor global burdens of diseaseCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 09, 2026
Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

|Jan 10, 2026
Perceptions of social determinants influencing cancer development, outcomes, and treatment toxicity among Spanish oncologists, nurses, and pharmacists: a cross-sectional survey.

Javier-David Benítez-Fuentes, Regina Gironés Sarrió, Victoria García Samblás

|Dec 10, 2025
Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions.

Regina Gironés Sarrió, Javier David Benítez Fuentes, Victoria García Samblás

|Nov 27, 2025
Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).

Silvia Masini, Monica Antoñanzas Basa, Antonio Calles

|Feb 25, 2025
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco

|Dec 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco

Pageof 3

Frequent Collaborators

3 joint publications

Juan José Soto-Castillo

3 joint publications

Alfredo Carrato

3 joint publications

Jorge Esteban-Villarrubia

2 joint publications

Teresa Alonso-Gordoa